Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Latest Information Update: 23 Sep 2024
At a glance
- Drugs Varnimcabtagene-Autoleucel (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Acronyms CART19-BE-01
Most Recent Events
- 01 Feb 2024 Results of updated outcomes published in the British Journal of Haematology.
- 12 Dec 2023 Results assessing long-term remission in CLL patients treated with CART19 therapy, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results of an intention to treat analysis using CAR-T cell product data from CART19-BE-01 trial and consecutive compassionate use and hospital exemption programs presented at the 65th American Society of Hematology Annual Meeting and Exposition